Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd

₹ 72.8 0.48%
24 Apr 2:52 p.m.
About

Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.

Key Points

Product Portfolio
a) Androstenedione which is used as Steroid Intermediate
b) Lovastatin used as Anti-cholesterol medication
c) Simvastatin is also used as Anti-cholesterol medication
d) Upcoming Products: Amlodipine, Cetirizine, Orlistat, Telmisartan, Serratiopepetidase and Phenylephrine. [1]

  • Market Cap 157 Cr.
  • Current Price 72.8
  • High / Low 94.0 / 59.2
  • Stock P/E
  • Book Value -50.3
  • Dividend Yield 0.00 %
  • ROCE -28.6 %
  • ROE %
  • Face Value 10.0

Pros

Cons

  • Company has low interest coverage ratio.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
9.58 15.86 6.76 11.98 21.81 19.16 10.64 20.94 9.09 11.46 10.58 14.89 12.98
15.23 20.38 13.29 19.76 31.71 28.94 16.91 22.84 12.07 16.08 13.20 15.79 15.07
Operating Profit -5.65 -4.52 -6.53 -7.78 -9.90 -9.78 -6.27 -1.90 -2.98 -4.62 -2.62 -0.90 -2.09
OPM % -58.98% -28.50% -96.60% -64.94% -45.39% -51.04% -58.93% -9.07% -32.78% -40.31% -24.76% -6.04% -16.10%
0.06 0.44 0.03 0.13 0.20 0.79 0.13 0.27 0.02 0.19 0.04 0.17 0.03
Interest 1.43 1.49 1.51 1.78 1.82 0.28 0.30 0.74 0.90 1.03 1.10 1.13 1.19
Depreciation 1.24 1.41 1.42 1.42 1.42 2.05 1.69 1.69 1.69 1.48 1.65 1.71 1.73
Profit before tax -8.26 -6.98 -9.43 -10.85 -12.94 -11.32 -8.13 -4.06 -5.55 -6.94 -5.33 -3.57 -4.98
Tax % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
-8.26 -6.99 -9.42 -10.85 -12.94 -11.31 -8.14 -4.06 -5.55 -6.94 -5.33 -3.57 -4.98
EPS in Rs -4.21 -3.56 -4.37 -5.03 -6.00 -5.25 -3.78 -1.88 -2.57 -3.22 -2.47 -1.66 -2.31
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Jun 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
69 11 0 0 1 3 34 48 33 54 60 52 50
73 24 4 5 14 11 41 58 52 71 94 68 60
Operating Profit -4 -13 -4 -5 -12 -8 -8 -10 -19 -18 -34 -16 -10
OPM % -5% -117% -1,088% -248% -22% -20% -56% -33% -57% -30% -20%
3 6 0 3 1 -0 -1 0 0 1 1 1 0
Interest 9 1 0 4 1 3 5 6 6 6 5 3 4
Depreciation 10 8 0 2 4 4 4 4 5 5 6 7 7
Profit before tax -19 -16 -4 -8 -16 -16 -18 -20 -29 -28 -45 -25 -21
Tax % 10% 5% -10% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-17 -15 -4 -8 -16 -16 -18 -20 -29 -28 -45 -25 -21
EPS in Rs -15.17 -13.22 -3.78 -6.82 -10.33 -9.67 -10.73 -12.03 -16.04 -14.45 -20.65 -11.45 -9.66
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 9%
3 Years: 16%
TTM: -17%
Compounded Profit Growth
10 Years: %
5 Years: -12%
3 Years: 5%
TTM: 28%
Stock Price CAGR
10 Years: 13%
5 Years: -7%
3 Years: -14%
1 Year: 0%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Figures in Rs. Crores

Mar 2012 Jun 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 10 10 10 10 13 14 14 17 18 20 22 22 22
Reserves 14 -2 -6 5 -4 -12 -32 -31 -43 -67 -97 -121 -130
Preference Capital 0 0 0 0 0 0 0 0 30 30 130 130
86 93 93 61 31 48 56 53 36 81 13 53 188
39 37 41 33 77 73 87 103 123 125 252 221 99
Total Liabilities 149 138 138 108 116 122 126 142 134 159 190 175 178
65 51 58 58 93 102 101 101 105 118 139 147 154
CWIP 0 7 0 0 11 4 4 3 4 12 8 4 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
83 80 80 50 13 16 21 38 24 29 43 24 24
Total Assets 149 138 138 108 116 122 126 142 134 159 190 175 178

Cash Flows

Figures in Rs. Crores

Mar 2012 Jun 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
7 -2 49 -45 -15 -11 -6 4 -36 -15 -17 -25
-1 6 0 -3 -4 -5 -3 -4 -10 -23 -23 -13
-6 -4 -49 54 13 16 9 17 29 38 40 37
Net Cash Flow 0 -0 0 6 -6 -0 0 17 -17 1 -1 -0

Ratios

Figures in Rs. Crores

Mar 2012 Jun 2013 Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 41 30 10 180 3 22 2 2 5 4
Inventory Days 286 2,368 14,704 2,162 337 142 345 234 230 170
Days Payable 256 1,517 32,250 4,360 510 339 521 292 340 217
Cash Conversion Cycle 70 881 -17,536 -2,018 -170 -175 -174 -57 -106 -44
Working Capital Days -6 -446 -6,532 -2,132 -275 -315 -267 -119 -200 -162
ROCE % -9% -15% -4% -8% -27% -27% -26% -36% -57% -42% -59% -29%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.72% 72.74% 72.74% 72.74% 72.74% 72.74%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.33% 0.50% 0.50% 0.50% 0.50% 0.50%
27.25% 27.25% 27.25% 27.25% 27.25% 27.26% 26.95% 26.76% 26.77% 26.76% 26.77% 26.75%
No. of Shareholders 7,0968,5718,1669,5319,5339,6509,2949,3159,3939,0308,9908,909

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents